Navigation Links
Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Date:4/28/2011

volve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); uncertainties related to the regulatory process; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
2. Keryx Biopharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
3. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
6. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
7. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
8. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
9. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Pa. , July 25, 2014 /PRNewswire-iReach/ -- ... and consulting for global corporations operating in highly ... host its first annual Global User Group Conference, ... historic Philadelphia, Pennsylvania at ... - http://photos.prnewswire.com/prnh/20140724/130263 This ...
(Date:7/24/2014)... July 24, 2014 Gain recognition ... Supply Chain of the biotech industry. Nominations are ... Awards, brought to you by the Bio ... of supply chain management professionals for the past ... stakeholders of the Biotech industry – Manufacturers, Service ...
(Date:7/24/2014)... Yung-Eun Sung has announced that they have developed ... which can be applied as high performance electrodes ... is both a group leader at the Center ... (IBS) and a professor at the Seoul National ... regards to the development of relative simplicity, scalablity, ...
(Date:7/24/2014)... 2014 Research and Markets has ... Proteomics Analytical Instruments Market 2014-2018" report to their ... Genomics is the study of the gene and ... structure and functions of proteomes or sets of proteins ... Genomics involves the mapping of genes and DNA sequencing ...
Breaking Biology Technology:Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2
... 14 CJPS Enterprises, LLC, the,operator of the ... put online more resources for Michigan companies looking ... grow their existing healthcare,business. Those resources can be ... is dedicated to providing users with information regarding,the ...
... China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky ... ,the Company,) (Amex: CSY ), a,leading ... drugs in the People,s Republic of China ... nasal spray for the treatment,and prevention of ...
... the Industry,s Largest eClinical Technology ... ... 14 PAREXEL International,Corporation (Nasdaq: PRXL ), a leading ... acquisition of,ClinPhone plc, a leading clinical technology organization. By combining,ClinPhone ...
Cached Biology Technology:The Michigan Life Sciences Pipeline Adds More Resources On Its Website 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 3PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5
(Date:7/25/2014)... 25 countries and 35 states will attend the ... Society of America (GSA) next week at the ... feature close to 500 presentations (including 70 talks) ... expression and regulation, functional genomics, chemical biology and ... variety of diseases. , Of special note ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... factor characterized by the existence of numerous isoforms ... to the protein deeply different characteristics. NRG1 plays ... during development and the different phases occurring after ... regrowth, remyelination and target reinnervation, Researchers at the ... soluble NRG1 upregulation observed in Schwann cells immediately ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... A majority of women with breast cancer today are candidates ... tissue. Results of a UC Davis study, however, show that ... breast are treated with a second lumpectomy rather than a ... years those women survive in half. "We were ...
... living in communities often rely on friends to help get ... of Cameron Currie at the University of Wisconsin-Madison, many microbes, ... Currie team,s study, which was funded by the National Science ... of the journal Science , describes the complex relationship ...
... Dunn Research Foundation has awarded a $3 million grant ... biomedical science that have the potential for clinical applications. ... researchers whose studies will be conducted at the Collaborative ... corner of University Boulevard and Main Street. To qualify ...
Cached Biology News:Second lumpectomy for breast cancer reduces survival rates 2Beetles get by with a little help from their friends 2
... used to reveal two distinct antigens in ... a Zymed polymer double staining detection method ... same human cell or tissue sample with ... using two different primary antibodies from mouse ...
... situ detection of apoptosis and mitochondrial membrane ... an early indication of the initiation of ... as a collapse in the electrochemical gradient ... the change in the membrane potential (YD). ...
... FLUOstar OPTIMA is a fully automated ... life science labs in academia and ... measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
... CYCLES. An assay kit designed to detect ... PARP is an enzyme implicated in DNA ... is cleaved by caspase-3. Cleavage of PARP ... kDa is a hallmark of apoptosis. Each ...
Biology Products: